Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (373)	11/12/1998 8:37:00 AM
From: Dr. John M. de Castro	Read Replies (2) \| Respond to of 1494

Annual Meeting Highlights biz.yahoo.com I hope that someone who attended the meeting will provide a report for this SI thread. The most significant thing mentioned in the press release is that participants in the open label portion of the trial are requesting continued treatment. The open label phase occurs after the double blind placebo controlled portion of the trial. In the open label phase, everyone is treated with memantine (no placebo) and everyone knows that they are being treated. The requests could be the result of a placebo effect. But, I doubt it. Placebo effects tend not to be very strong in dementia. Thus, this is a very promising clue. John de C